由于与辉瑞达成合作，三生国健（688336.SH）2025年业绩大涨。根据公司发布的业绩快报，2025年三生国建实现营业收入41.99亿元，较上年增加 251.81%；实现归母净利润29.39亿元，较上年涨幅317.09%。 同时，扣除本年度确认的政府补助收益、理财产品利息收入、固定资产处置损失、参股公司分红收益及营业外支出后，实现扣非净利润28.05亿元，涨幅 1041.01%。 三生国健在业绩快报中指出，营业总收入、归母净利润、扣非净利润、基本每股收益、总资产等指标相比上年同期均出现较大幅度增长，主要由于报告期内 公司与辉瑞公司（Pfizer Inc.）达成重要合作，公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元。 2025年5月20日，三生国健的母公司三生制药（01530.HK）与辉瑞关于PD-1/VEGF双特异性抗体SSGJ-707的交易发布，此次交易达成12.5亿美元不可退还且 不可抵扣的首付款。 在达成重磅交易的同时，三生国健或将面临PD-1/VEGF双抗赛道日趋激烈的市场竞争。作为近年来备受瞩目的明星靶点，该赛道入局者众多、竞争激烈。 Insight数据库显示，目 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].